<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444012</url>
  </required_header>
  <id_info>
    <org_study_id>D5130R00052</org_study_id>
    <nct_id>NCT03444012</nct_id>
  </id_info>
  <brief_title>ADHERE-S (NIS Brilique)</brief_title>
  <official_title>Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      noninterventional study investigating persistence and adherence on ticagrelor in ACS patients
      in Serbia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome</measure>
    <time_frame>1 year (12 months)</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>ACS (Acute Coronary Syndrome)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor 90 mg</intervention_name>
    <description>persistence and adherence on ticagrelor in ACS patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ACS patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively
             treated

          -  Patients already on treatment with ticagrelor at least for 1 month and no longer than
             3 months prior to study initiation. Enrolment in this study must not be trigger for
             ticagrelor initiation.

          -  read and signed the Informed Consent Form

        Exclusion Criteria:

        Any contraindications as per approved SmPC of Brilique

        • Patients with life-threatening conditions which could disable patients to comply with
        scheduled visits and/or not able to fill in the patient questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mirjana Petrovic, PhD</last_name>
    <phone>+381113336900</phone>
    <email>mirjana.petrovic@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

